SEARCH

SEARCH BY CITATION

References

  • ALBRIGHT, J.D., REICH, M.F., DELOS SANTOS, E.G., DUSZA, J.P., SUM, F.W., VENKATESAN, A.M., COUPET, J., CHAN, P.S., RU, X., MAZANDARANI, H. & BAILEY, T. (1998). 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem., 41, 24422444.
  • ALLISON, N.L., ALBRIGHTSON-WINSLOW, C.R., BROOKS, D.P., STASSEN, F.L., HUFFMAN, W.F., STOTE, R.M. & KINTER, L.B. (1988). Species heterogeneity and antidiuretic hormone antagonists: what are the predictors?. In: Vasopressin: Cellular and Integrative Functions, ed. Cowley, A.W., Liard, J.F. & Ausiello, D.A. pp. 207214. New York, NY: Raven Press Ltd.
  • ARROYO, V., CLÀRIA, J., SALÓ, J. & JIMÉNEZ, W. (1994). Antidiuretic hormone and pathogenesis of water retention in cirrhosis with ascites. Semin. Liver Dis., 14, 4458.
  • ARROYO, V. & JIMÉNEZ, W. (2003). Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology, 37, 1315.
  • BELLISANT, E., DENOLLE, T., SINNASSAMY, P., BICHET, D.G., GIUDICELLI, J.F., LECOZ, F., GANDON, J.M. & ALLAIN, H. (1996). Systemic and regional hemodynamic and biological effects of a new κ-opioid agonist, niravoline, in healthy volunteers. J. Pharmacol. Exp. Ther., 278, 232242.
  • BOSCH-MARCÉ, M., JIMÉNEZ, W., ANGELI, P., LEIVAS, A., CLÀRIA, J., GRAZIOTTO, A., ARROYO, V., RIVERA, F. & RODÉS, J. (1995). Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology, 109, 217223.
  • BOSCH-MARCE, M., POO, J.L., JIMÉNEZ, W., BORDAS, N., LEIVAS, A., MORALES-RUIZ, M., MUÑOZ, R.M., PÉREZ, M., ARROYO, V., RIVERA, F. & RODÉS, J. (1999). Comparison between two aquaretic drugs (niravoline vs OPC-31260) in cirrhotic rats with ascites and water retention. J. Pharmacol. Exp. Ther., 289, 194201.
  • CAMPS, J., SOLÁ, J., ARROYO, V., PÉREZ-AYUSO, R.M., GAYA, J., RIVERA, F. & RODÉS, J. (1987). Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology, 93, 498505.
  • CLÀRIA, J. & JIMÉNEZ, W. (1999). Renal dysfunction and ascites in carbon-tetrachloride-induced cirrhosis in rats. In: Ascites and Renal Dysfunction in Liver Disease. Pathogenesis Diagnosis and Treatment, ed. Arroyo, V., Ginès, P., Rodés, J., Schrier, R.W., pp. 379396. Blackwell: Science Inc.
  • CLÀRIA, J., JIMÉNEZ, W., ARROYO, V., LA VILLA, G., LÓPEZ, C., ASBERT, M., CASTRO, A., GAYA, J., RIVERA, F. & RODÉS, J. (1991). Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology, 100, 494501.
  • FERNÁNDEZ-VARO, G., ROS, J., CEJUDO-MARTÍN, P., CANO, C., ARROYO, V., RIVERA, F., RODÉS, J. & JIMÉNEZ, W. (2003). Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J. Hepatol., 38, 755761.
  • GERBES, A.L., GÜLBERG, V., GINÈS, P., DECAUX, G., GROSS, P., GANDJINI, H., DJIAN, J. & The VPA Study Group (2003). Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology, 124, 933939.
  • GUYADER, D., PATAT, A., ELLIS-GROSSE, E.J. & ORCZYK, G.P. (2002). Pharmacodynamic effect of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology, 36, 11971205.
  • HAMON, G. & JOUQUEY, S. (1990). Kappa agonists and vasopressin secretion. Horm. Res., 34, 129132.
  • JARD, S. (1988). Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int., 34, S38S42.
  • JIMÉNEZ, W., MARTINEZ-PARDO, A., ARROYO, V., BRUIX, J., RIMOLA, A., GAYA, J., RIVERA, F. & RODÉS, J. (1985). Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology, 5, 245250.
  • JIMÉNEZ, W., SERRADEIL-LE GAL, C., ROS, J., CANO, C., CEJUDO, P., MORALES-RUIZ, M., ARROYO, V., PASCAL, M., RIVERA, F., MAFFRAND, J.P. & RODÉS, J. (2000). Long-term aquaretic efficacy of a selective nonpeptide V2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J. Pharmacol. Exp. Ther., 295, 8390.
  • LEE, C.R., WATKINS, M.L., PETTERSON, J.H., GATTIS, W., O'CONNOR, C.M., GHEORGHIADE, M. & ADAMS, K.F. (2003). Vasopressin: a new target for the treatment of heart failure. Am. Heart J., 146, 918.
  • MANNING, M., PRZYBYLSKI, J.P., OLMA, A., KLIS, W.A., KRUSZYNSKI, M., WO, N.C., PELTON, G.H. & SAWYER, W.H. (1987). No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature, 329, 839840.
  • MATTHEWS, J.M., HOEKSTRA, W.J., DYATKIN, A.B., HECKER, L.R., HLASTA, D.J., POULTER, B.L., ANDRADE-GORDON, P., DE GARAVILLA, L., DEMAREST, K.T., ERICSON, E., GUNNET, J.W., HAGEMAN, W., LOOK, R., MOORE, J.B., REYNOLDS, C.H. & MARYANOFF, B.E. (2004). Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg. Med. Chem. Let., 14, 27472752.
  • NIELSEN, S., FROKIAER, J., MARPLES, D., KWON, T.H., AGRE, P. & KNEPPER, M.A. (2002). Aquaporins in the kidney: from molecules to medicine. Physiol. Rev., 82, 205244.
  • PÉREZ-AYUSO, R.M., ARROYO, V., CAMPS, J., JIMÉNEZ, W., RODAMILANS, M., RIMOLA, A., GAYA, J., RIVERA, F. & RODÉS, J. (1984). Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhosis. Nephron, 36, 3037.
  • SAWYER, W.H., PANG, P.K.T., SETO, J., MCENROE, M., LAMMEK, B. & MANNING, M. (1981). Vasopressin analogues that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science (Washington, DC), 312, 4951.
  • SERRADEIL-LE GAL, C. (1998). Nonpeptide antagonist for vasopressin receptors-pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist. Vasopressin Oxytocin, 449, 427438.
  • SLIZGI, G.R. & LUDENS, J.H. (1982). Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J. Pharmacol. Exp. Ther., 220, 585591.
  • TAHARA, A., TOMURA, Y., WADA, K., KUSAYAMA, T., TSUKADA, J., TAKANASHI, M., YATSU, T., UCHIDA, W. & TANAKA, A. (1997). Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther., 282, 301308.
  • UDELSON, J.E., SMITH, W.B., HENDRIX, G.H., PAICHAUD, C.A., GHAZZI, M., THOMAS, I., GHALI, J.K., SELARU, P., CHANOINE, F., PRESSLER, M.L. & KONSTAM, M.A. (2001). Acute hemodynamic effects of Conivaptan, a dual V1A vasopressin receptor antagonist, in patients with advanced heart failure. Circulation, 104, 24172423.
  • WONG, F., BLEI, A.T., BLENDIS, L.M., THULUVATH, P.J. & for The North American VPA-985 Study Group (2003). A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter randomized placebo-controlled trial. Hepatology, 37, 182191.
  • WONG, LL. & VERBALIS, J.G. (2001). Vasopressin V2 receptor antagonists. Cardiovasc. Res., 51, 391402.
  • YAMAMURA, Y., OGAWA, H., YAMASHITA, H., CHIHARA, T., MIYAMOTO, H., NAKAMURA, S., ONOGAWA, T., YAMASHITA, T., HOSOKAWAM, T., MORI, T., TOMINAGA, M. & YABUUCHI, Y. (1992). Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol., 105, 787791.